Naronapride
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Naronapride
- Molecular weight
- 537.1
- Structure (SMILES)
- COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCCCC(=O)O[C@H]2CN3CCC2CC3)C[C@@H]1OC
- 1 piperidinehexanoic acid 4 4 amino 5 chloro 2 methoxybenzoyl amino 3 methoxy 1 azabicyclo 2 2 2 oct 3 yl ester 3s 4r
- 1-PIPERIDINEHEXANOIC ACID, 4-((4-AMINO-5-CHLORO-2-METHOXYBENZOYL)AMINO)-3-METHOXY-, 1-AZABICYCLO(2.2.2)OCT-3-YL ESTER, (3S,4R)-
- 20 mg ati 7505
- 20 mg ATI 7505
- 40 mg ATI 7505
- 80 mg ATI 7505
- ati 7505
- ATI-7505
- ati7505
- ATI7505
- naronaprida
- Naronaprida
- naronapride
- Naronapride
- naronapride [INN]
- NARONAPRIDE [USAN]
- Naronapride [WHO-DD]
- naronapride inn
- naronapride usan
- naronapride who dd
- CAS registry numbers
- 860174-12-5
- ChEMBL ID
- CHEMBL2103858
- InChIKey
- VGDDOIZXGFJDRC-VJTSUQJLSA-N
- PubChem compound IDs
- 11237985
- FDA ingredient codes (UNII)
- 058896B00B
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -pride
Mechanisms of action
- Mechanism
- Serotonin 4 (5-HT4) receptor agonist
- Action type
- Agonist
- Target
- 5-hydroxytryptamine receptor 4
- Protein identifier
- Q13639
Open Targets mechanisms
- Mechanism
- Serotonin 4 (5-HT4) receptor agonist
- Action type
- Agonist
- Target
- 5-hydroxytryptamine receptor 4
Investigated indications
- Condition
- Gastroparesis
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000948
- Subject identifier
- D018589
- Condition identifier
- EFO_0003948
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000948
- Highest recorded phase
- 2
- Condition identifier
- HP_0002019
- Highest recorded phase
- 2
- Condition identifier
- HP_0012450
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006769
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007186
- Highest recorded phase
- 2
Trial references
- NCT05621811
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 2
- Polar surface area
- 106.36
- Calculated partition coefficient (ALogP)
- 2.95
- Calculated partition coefficient (XLogP)
- 2.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 11
- Heavy atoms
- 37
- Molecular formula
- C27H41ClN4O5
- Monoisotopic mass
- 536.2765481
- Natural product
- Yes
- Serotonin 5-HT4 Receptor Agonists
Related records
Trials (4)
- A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome
- Different Doses of Naronapride vs. Placebo in Gastroparesis
- Effect of ATI-7505 on Gastrointestinal Transit in Healthy Volunteers
- Phase II, Randomized, Placebo-Controlled Study of ATI-7505 in Patients With Chronic Idiopathic Constipation
In development for (2)
- Gastroesophageal reflux disease Phase 2
- Gastroparesis Phase 2
Targets (1)
- HTR4 Serotonin 4 (5-HT4) receptor agonist